World Health Organization Issues Warning Over Severe Lack of Obesity Injections
Under one in 10 people eligible to benefit from weight-loss injections like Wegovy have access to them, states the global health agency as it issues its initial advice on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging broader and more equitable availability to GLP-1 medication.
Per projections, more than two billion are projected to be obese by 2030 without intervention.
"The new guidance affirms that obesity is a long-term condition that can be treated with thorough and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are key obstacles to widespread access to the jabs that can aid individuals in losing substantial body mass, notes the body.
Weight-Loss Drug Scarcity
Even in the current best projected case, the supply of these medications could only cover approximately 100 million people – under 10% of eligible patients, according to the WHO.
The recommendation encourages countries and companies to widen availability, by measures including patent sharing.
Exclusive production rights on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
How Obesity Jabs Function
These medications imitate a biological compound to slow digestion, curb appetite and increase feelings of fullness so users eat less.
Patients commonly see weight reduction within a few weeks of beginning the once-weekly jabs.
Research points to people may put most of the weight back on a year later of stopping the drug, as their typical hunger resume.
To be carrying excess weight elevates your likelihood for contracting medical conditions, including diabetes, heart disease, brain attack, and specific cancers.
Obesity affects people in every country and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
